Recombinant protein subunit COVID‐19 vaccine‐induced Guillain‐Barré Syndrome in an adolescent: A case report
- 1 August 2022
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (2) , 556-560
Abstract
Guillain‐Barré Syndrome (GBS), an autoimmune neurological disease of peripheral nerves, has been causally associated with COVID‐19 vaccination in adults. However, no such report has been published so far in children. We describe a 13‐year‐old female child who presented to the emergency department with complaints of bilateral upper limb, lower limb and truncal weakness over 3 days following first dose of recombinant protein subunit COVID‐19 vaccine (Corbevax). Clinical examination and nerve conduction studies showed pure motor axonal polyneuropathy with absent compound muscle action potential (CMAP) in all sampled nerves of upper and lower limbs which was consistent with the diagnosis of GBS after ruling out possible alternative aetiologies. A temporal association between first dose of protein subunit COVID‐19 vaccine administered a day prior and symptom onset was noted. The causality assessment using the World Health Organization (WHO) tool for adverse event following immunization (AEFI) assessment indicated vaccine product‐related reaction categorized as A1. The patient's clinical condition improved after seven sessions of plasmapheresis. The purpose of this report is to create awareness among health care professionals about COVID‐19 vaccine‐induced GBS in children as early diagnosis and management can be critical in avoiding complications and improving patient outcomes.Keywords
All Related Versions
This publication has 12 references indexed in Scilit:
- Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?Clinical Neurology and Neurosurgery, 2021
- Case of Guillain-Barré syndrome following COVID-19 vaccineBMJ Case Reports, 2021
- Guillain‐Barré Syndrome following ChAdOx1‐S/nCoV‐19 VaccineAnnals of Neurology, 2021
- Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1BMJ Case Reports, 2021
- Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 VaccineCureus, 2021
- Guillain-Barré Syndrome in a 67-year-old Male Post COVID-19 Vaccination (Astra Zeneca)American Journal of Medical Case Reports, 2021
- Regional variation of Guillain-Barré syndromeBrain, 2018
- Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in KoreaJournal of Korean Medical Science, 2017
- Guillain–Barré syndrome in general practice: clinical features suggestive of early diagnosisBritish Journal of General Practice, 2016
- Vaccination and Autoimmunity—‘vaccinosis’: A Dangerous Liaison?Journal of Autoimmunity, 2000